IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Condition:   Ovarian Cancer Recurrent Interventions:   Drug: IN10018;   Drug: Placebo of IN10018;   Drug: Pegylated Liposomal Doxorubicin Sponsor:   InxMed (Shanghai) Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials